Successful performance of TIL therapy in patients with advanced melanoma and concomitant CLL/SLL may be challenging due to the potential contamination of the harvested tumor sample with SLL and IL-2-induced ex vivo modulation of atypical B lymphocytes (14). The gene discussed is IL2; the disease is B-cell chronic lymphocytic leukemia.